US Post-Market Surveillance Study of the Surfacer System
← catalyst calendarNCT05050799 · readout in 118 d
Sponsored by Merit Medical Systems, Inc. (industry) · MMSI — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
30estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-08 | actual | When the study began enrolling |
| Primary completion | 2026-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Disease
Intervention
- Device: Central Venous Access
Primary outcomes
what the primary-completion date above is the date OFCentral Venous Access operational
measured 24 hours
Incidence of adverse events through 24 hours
measured 24 hours
Permalink · MMSI's whole pipeline · Catalyst calendar · Every registered study · What changed